Be Biopharma

Be Biopharma: Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body’s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Listing
Private
Therapeutic Modalities
Antibodies, B Cell, Cell Therapy
Website:
Address:
One Kendall Sq.
B200 Suite 001
Cambridge, MA 02139
United States

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • Mitchell Chan, CFO

Upcoming Company Event Participation